90 likes | 234 Views
Level of viraemia and genotype characteristics of Parvo B19 in blood donors and patients. Brojer E, Grabarczyk P Depatment of Immuhematology Institute of Hematology and Blood Transfusion, Warsaw, Poland. Parvo B19 testing in IHBT. MATERIALS
E N D
Level of viraemia and genotype characteristics of Parvo B19 in blood donors and patients Brojer E, Grabarczyk P Depatment of Immuhematology Institute of Hematology and Blood Transfusion, Warsaw, Poland
Parvo B19 testing in IHBT MATERIALS • plasma pools of 24 donations for anti-D and anti-HBs • plasma from patients with clinical symptoms METHODS • Quantitative real-time PCR • Qiagen/Nuclisens Extractor + home made (Aberham C, 2001). • Qiagen + RealArt Parvo (B19 PE PCR Kit, Artus Biotech) • quantitative anti-B19 IgG and IgM • recomWell Parvowirus B19 IgG and IgM (MIKROGEN GmbH) • genotyping • sequencing of NS1/VP1 (Servant A, 2002)
Parvo B19 genotype 2 infection after kidney transplantation pregnancy • BD, (dr A.Wieczorek - Transplantation Ward, Poznań) • 11.2003 kidney transplantation • 02.2004 red cell aplasia • 18.03.2004 DNA B19 (+) • the and of March 2004 immunosupresion treatment switch • April 2004 clinical parameters in the normal range • May 2004 – January 2005 - pregnancy (no clinical sympthoms)
B19 genotype 1 infection in symptomless blood donor • blood donor (PK), donor of plasma for anti-HBs production (RCKiK Poznań) • 38 years old, 3 children, • throughout observation period (3 years and 3 months) no clinical symptoms: Hb, Ht, PLT, RBC, WBC, ALT in normal range.
Anaemia after allo BMT due to the parvo B19 genotype 1 infection transmitted by BM donor • B19 DNA detected in pretransplant DNA sample of the donor was 100% homologous to B19 DNA of the patient
Comparison of genotyp 1 and 2 sequences from patients with aplastic anaemia
Observations and discussion • Genotype 1 and genotype 2 were identified in clinical speciments from patients with similar symptoms • Should NAT for plasma screenig identify not only genotype 1 but also genotype 2? ( and genotype 3, PARV 4, PARV5) • B19 transmission by bone marrow cells • Should BM/SC or other tissue or organ donors (especially young) be tested for B19 markers? • Correlation of B19 viral load with clinical manifestations – • high viremia during syptoms in most but not all patients